Novavax, Inc.’s recombinant nanoparticle protein-based COVID-19 vaccine, NVX-CoV2373, demonstrated 100% protection against moderate and severe disease, 90.4% efficacy overall, and met the primary endpoint in its PREVENT-19 pivotal Phase 3 trial. The study enrolled 29,960 participants across 119 sites in the U.S. and Mexico to evaluate efficacy, safety and immunogenicity.   The company intends to file for regulatory authorizations in the third quarter, upon completion of the final phases of pro...